Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1964 2
1977 2
1978 3
1979 1
1980 2
1982 4
1983 2
1984 1
1986 1
1987 1
1988 2
1989 2
1991 2
1992 4
1993 3
1994 8
1995 9
1996 4
1997 5
1998 4
1999 12
2000 8
2001 6
2002 6
2003 6
2004 8
2005 2
2006 12
2007 10
2008 11
2009 18
2010 17
2011 15
2012 29
2013 28
2014 27
2015 44
2016 40
2017 48
2018 46
2019 61
2020 54
2021 48
2022 85
2023 53
2024 68
2025 93
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

803 results

Results by year

Filters applied: . Clear all
Page 1
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
D'Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, Krueger K, Laskowski J, Li X, Lissoos T, Milata J, Morris N, Arora V, Milch C, Sandborn W, Sands BE; LUCENT Study Group. D'Haens G, et al. N Engl J Med. 2023 Jun 29;388(26):2444-2455. doi: 10.1056/NEJMoa2207940. N Engl J Med. 2023. PMID: 37379135 Clinical Trial.
Reply.
De Voogd F, D'Haens GR, Gecse KB. De Voogd F, et al. Gastroenterology. 2023 Jun;164(7):1347-1348. doi: 10.1053/j.gastro.2023.01.044. Epub 2023 Feb 17. Gastroenterology. 2023. PMID: 36801272 No abstract available.
Reply.
Anjie SI, D'Haens GR. Anjie SI, et al. Clin Gastroenterol Hepatol. 2025 Jun 30:S1542-3565(25)00539-7. doi: 10.1016/j.cgh.2025.06.018. Online ahead of print. Clin Gastroenterol Hepatol. 2025. PMID: 40602741 No abstract available.
Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn's Disease: Results From the Phase 3 GRAVITI Study.
Hart A, Panaccione R, Steinwurz F, Danese S, Hisamatsu T, Cao Q, Ritter T, Seidler U, Olurinde M, Vetter ML, Yee J, Yang Z, Wang Y, Johanns J, Han C, Sahoo A, Terry NA, Sands BE, D'Haens G; GRAVITI Study Group. Hart A, et al. Gastroenterology. 2025 Aug;169(2):308-325. doi: 10.1053/j.gastro.2025.02.033. Epub 2025 Mar 18. Gastroenterology. 2025. PMID: 40113101 Free article. Clinical Trial.
Reply.
D'Haens GR, Sandborn WJ. D'Haens GR, et al. Gastroenterology. 2023 Jan;164(1):166-168. doi: 10.1053/j.gastro.2022.09.001. Epub 2022 Sep 5. Gastroenterology. 2023. PMID: 36067821 No abstract available.
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P; SONIC Study Group. Colombel JF, et al. N Engl J Med. 2010 Apr 15;362(15):1383-95. doi: 10.1056/NEJMoa0904492. N Engl J Med. 2010. PMID: 20393175 Free article. Clinical Trial.
Reply.
D'Haens G, Vermeire S, Laharie D. D'Haens G, et al. Gastroenterology. 2018 Oct;155(4):1278-1279. doi: 10.1053/j.gastro.2018.09.027. Epub 2018 Sep 17. Gastroenterology. 2018. PMID: 30236558 No abstract available.
Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials.
D'Haens G, Higgins PDR, Peyrin-Biroulet L, Sands BE, Lee S, Moses RE, Redondo I, Escobar R, Hunter Gibble T, Keohane A, Morris N, Zhang X, Arora V, Kobayashi T. D'Haens G, et al. Inflamm Bowel Dis. 2024 Dec 5;30(12):2335-2346. doi: 10.1093/ibd/izae004. Inflamm Bowel Dis. 2024. PMID: 38271613 Free PMC article. Clinical Trial.
803 results